Business
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
--Data will be presented at the conference in October in Montreal Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"--Data will be presented at the conference in October in Montreal\nMarlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about INTASYL, its patented technology platform at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting. The conference will be held from October 6th-9th in Montreal, bringing together leading experts in oligonucleotide research.\nPhio's presentation will focus on how INTASYL can enhance the ex vivo expansion process to improve the functionality and outcomes of adoptive cell therapies such as NK, TIL, or CAR-T. An advantage of the INTASYL technology is its simplified chemical composition, designed to reduce toxicity and improve both tolerability and efficacy, which are concerns in therapeutic development.\nPresentation Details are as follows:\n\n\n\nTitle:\nINTASYL® Self-Delivering RNAi: a Flexible Platform for Cancer Treatment\n\n\nPoster Number:\nP180\n\n\nPoster Session:\nII\n\n\nPresenting Author:\nMelissa Maxwell\n\n\nDate and Time:\nOctober 8 at 3:45-6:45 PM\n\n\nLocation:\nCentre Mont-Royal, 2000 Mansfield St, Montreal, Quebec\n\n\n\n \nAbout Phio Pharmaceuticals Corp.\nPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. In non-systemic applications, INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.\nFor additional information, visit the Company's website, www.phiopharma.com.\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as \"intends,\" \"believes,\" \"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \...